Inhibition of chemical-induced experimental cancer by synthetic phenolic antioxidants.
Williams
G M
GM
American Health Foundation, Valhalla, NY 10595.
D015073:2-Acetylaminofluorene; D016604:Aflatoxin B1 / Q000009:adverse effects; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D000975:Antioxidants / Q000008:administration & dosage; D002083:Butylated Hydroxyanisole / Q000494:pharmacology*; D002084:Butylated Hydroxytoluene / Q000009:adverse effects / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D051379:Mice; D051381:Rats; D011916:Rats, Inbred F344; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced
D016588:Anticarcinogenic Agents; D000975:Antioxidants; D002084:Butylated Hydroxytoluene; D002083:Butylated Hydroxyanisole; D015073:2-Acetylaminofluorene; D016604:Aflatoxin B1